Electronic Study for Anastrozole Pharmacovigilance Evaluation

Collecting information regarding adverse events from patients on treatment with anastrazole with early stage breast cancer

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Early Breast Cancer Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Sex eligibility

Female

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Post-menopausal Early Invasive Breast Cancer Patients who are under anastrazole treatment, who have normal renal and hepatic functions.

Exclusion criteria

Metastatic breast cancer patients, previous hormonal therapy, other malignancies.

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Acronym: E-SAFE

Important dates

Study start: 2004
Study completion: 2008
First posted: Nov 14, 2007
Registry last updated: Jul 28, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed